Novartis, Entresto
Digest more
Novartis has started to show the effects of its patent cliff more strongly, with sales and profits falling in the first ...
Generic competition for Promacta, a blood disorder drug, and Tasigna, a leukemia treatment, is adding pressure on Novartis ...
The stock is down on a predictable, already-announced Entresto patent cliff (Entresto -42% YoY in Q1) and the market is ...
As blockbuster heart failure drug Entresto inches toward a patent cliff, Novartis is calling on the FDA—again—to keep early-bird generics at bay. At the time, Novartis argued greenlighting any ...
NVS' Q1 miss reflects Entresto and Promacta generic hits, even as Kisqali, Pluvicto and Leqvio deliver strong growth and ...
Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with ...
Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as ...
After Eli Lilly and Boehringer Ingelheim posted a landmark win for their diabetes drug Jardiance in heart failure patients with preserved ejection fraction earlier this month, the pressure is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results